Skip to main content
SpringerLink
Log in

PPI therapy

The small bowel, low-dose aspirin and PPIs—should we be concerned?

  • News & Views
  • Published:

From Nature Reviews Gastroenterology & Hepatology

View current issue Sign up to alerts

A new study suggests that co-prescription of low-dose aspirin and PPIs increases the incidence of small-bowel mucosal breaks. Should we be concerned about the potential negative interactions of these drugs? Or is the balance of evidence still substantially tipped towards the need for PPIs to protect against aspirin-induced upper gastrointestinal damage?

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Balancing the potential risks and benefits of long-term aspirin and PPI use.

References

  1. Lanas, A., Wu, P., Medin, J. & Mills, E. J. Low doses of acetylsalicylic acid increase risk of gastrointestinal bleeding in a meta-analysis. Clin. Gastroenterol. Hepatol. 9, 762–768 (2011).

    Article  CAS  PubMed  Google Scholar 

  2. Bhatt, D. L. et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J. Am. Coll. Cardiol. 52, 1502–1517 (2008).

    Article  PubMed  Google Scholar 

  3. Endo, H. et al. Risk factors for small-bowel mucosal breaks in chronic low-dose aspirin users: data from a prospective multicenter capsule endoscopy registry. Gastrointest. Endosc. http://dx.doi.org/10.1016/j.gie.2014.03.024.

  4. Wallace, J. L. et al. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology 141, 1314–1322 (2011).

    Article  CAS  PubMed  Google Scholar 

  5. Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373, 1849–1860 (2009).

  6. Kelly, J. P. et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 348, 1413–1416 (1996).

    Article  CAS  PubMed  Google Scholar 

  7. Casado Arroyo, R. et al. Lower GI bleeding is more common than upper among patients on dual antiplatelet therapy: long-term follow-up of a cohort of patients commonly using PPI co-therapy. Heart 98, 718–723 (2012).

    Article  PubMed  Google Scholar 

  8. Miyamoto, M. et al. Continuous proton pump inhibitor treatment decreases upper gastrointestinal bleeding and related death in rural area in Japan. J. Gastroenterol. Hepatol. 27, 372–377 (2012).

    Article  CAS  PubMed  Google Scholar 

  9. Lanas, A. et al. A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal anti-inflammatory drug use. Am. J. Gastroenterol. 100, 1685–1693 (2005).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University Clinic Hospital, University of Zaragoza, CIBERehd, IIS Aragón, Calle de San Juan Bosco 15, Zaragoza, 5009, Spain

    Angel Lanas & Carlos Sostres

Authors
  1. Angel Lanas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carlos Sostres
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Angel Lanas.

Ethics declarations

Competing interests

A.L. has received funding from Astra-Zeneca, Bayer and Pfizer. C.S. declares no competing interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lanas, A., Sostres, C. The small bowel, low-dose aspirin and PPIs—should we be concerned?. Nat Rev Gastroenterol Hepatol 11, 458–460 (2014). https://doi.org/10.1038/nrgastro.2014.120

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrgastro.2014.120

  • Springer Nature Limited

Search

Navigation